Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery by Di Trani, Nicola et al.
04 August 2020
POLITECNICO DI TORINO
Repository ISTITUZIONALE
Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery / Di Trani, Nicola; Silvestri,
Antonia; Sizovs, Antons; Wang, Yu; R. Erm, Donald; Demarchi, Danilo; Liu, Xuewu; Grattoni, Alessandro. - In: LAB ON A
CHIP. - ISSN 1473-0189. - ELETTRONICO. - (2020).
Original
Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery
Publisher:
Published
DOI:10.1039/d0lc00121j
Terms of use:
openAccess
Publisher copyright
(Article begins on next page)
This article is made available under terms and conditions as specified in the  corresponding bibliographic description in
the repository
Availability:
This version is available at: 11583/2826592 since: 2020-05-18T19:08:31Z
Royal Society of Chemistry
Lab on a Chip
PAPER
Cite this: DOI: 10.1039/d0lc00121j
Received 5th February 2020,
Accepted 27th March 2020
DOI: 10.1039/d0lc00121j
rsc.li/loc
Electrostatically gated nanofluidic membrane for
ultra-low power controlled drug delivery†
Nicola Di Trani, ‡ab Antonia Silvestri, ‡ac Antons Sizovs,a Yu Wang,a
Donald R. Erm,a Danilo Demarchi, c Xuewu Liua and Alessandro Grattoni *ade
Patient-centered therapeutic management for chronic medical conditions is a desired but unmet need, largely
attributable to the lack of adequate technologies for tailored drug administration. While triggered devices that
control the delivery of therapeutics exist, they often rely on impractical continuous external activation. As such,
next generation continuously tunable drug delivery systems independent of sustained external activation
remain an elusive goal. Here we present the development and demonstration of a silicon carbide (SiC)-coated
nanofluidic membrane that achieves reproducible and tunable control of drug release via electrostatic gating.
By applying a low-intensity voltage to a buried electrode, we showed repeatable and reproducible in vitro
release modulation of three model analytes. A small fluorophore (Alexa Fluor 647), a large polymer
polyĲsodium 4-styrenesulfonate) and a medically relevant agent (DNA), were selected as representatives of
small molecule therapeutics, polymeric drug carriers, and biological therapeutics, respectively. Unlike other
drug delivery systems, our technology performed consistently over numerous cycles of voltage modulation,
for over 11 days. Importantly, low power consumption and minimal leakage currents were achieved during the
study. Further, the SiC coating maintained integrity and chemical inertness, shielding the membrane from
degradation under simulated physiological and accelerated conditions for over 4 months. Through leveraging
the flexibility offered by electrostatic gating control, our technology provides a valuable strategy for tunable
delivery, setting the foundation for the next generation of drug delivery systems.
Introduction
Personalized care and precision medicine are emerging as
fundamental approaches for the prevention and treatment of
pathologies. Patient-focused therapeutic management can be
achieved by taking into account genetics, patient-to-patient
variability, and environmental conditions.1 Such approaches
challenge the widespread ‘one-size-fits-all’ paradigm where
treatment and prevention are designed around conventional
disease archetypes. Despite the substantial resources dedicated
to achieving precision medicine, personalized prevention and
treatment remain largely unmet clinical needs.
Patient-focused therapeutic management requires
advanced technologies for tailored drug administration. For
example, sensors are needed for continuous monitoring of
intra- and inter-patient variabilities to effectively achieve an
individualized approach. Further, drug delivery technologies
that allow for ad hoc rapid and simple adjustment of drug
doses represent a desirable feature. An ideal drug delivery
system includes integration of the following factors: 1)
sensing of physical or biological signals that can trigger the
release, adjustment or interruption of drug release, 2) a drug
delivery actuator that can continuously modulate, activate or
interrupt the drug administration, 3) a feedback loop
architecture that allows for further control of drug release, 4)
remote communication and control capabilities to enable
clinicians to adjust drug delivery independently. In the
pursuit of such technology, wearable and implantable
systems have gained significant interest. This is especially
evident in the management of chronic diseases such as type
1 diabetes,2–4 and posterior eye conditions in
ophthalmology,5 among others, where continuous
monitoring and adjustment of drug doses are imperative.
Along with offering long-term controlled drug delivery,
implants can eliminate the widespread issue of non-
compliance to treatment,6 and pill- and treatment-fatigue.
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Non-adherence to chronic medications is reported at a
staggering ∼50%,7 accounting for up to 50% of treatment
failures, 125 000 deaths, and approximately 25% of
hospitalizations in the United States, yearly.8 Another
important consideration is that implantable systems can
offer enhanced bioavailability of drugs, afford lower drug
doses and hence reduce adverse effects by keep drug
concentration within the therapeutic window, as well as avoid
the onset of drug resistance.9
Considering the vast opportunities offered by autonomous
“smart” delivery, numerous sensing technologies have been
developed.10,11 Notable examples are glucose monitoring
devices,12 implantable sensors for heart failure,13 and
epidermal wearable systems,14 among others. Despite
significant developments in sensing technologies, there is a
lack of implantable drug delivery actuators that could be
interfaced with sensors to yield a technological platform
capable of personalized patient care.
Current approaches to tunable drug delivery systems are
comprised of stimuli responsive devices. These devices rely
on membranes that can change their permeability to drug
upon external excitation. Particle embedded membranes that
respond to a magnetic field,15 near-infrared irradiation,16,17
or ultrasound18 are notable examples. The embedded
particles increase the temperature locally upon external
excitation, generating a conformational change in the
polymeric structure and increasing the membrane
permeability. Alternatively, magnetic particles, can be
controlled by an external magnetic field and can act as valves
to open or close the membrane.19,20 These technologies are
valuable strategies for controllable drug delivery. However,
they require continuous external intervention to function,
which compromises their application to the next generation
of autonomous drug delivery systems.
Generally, an ideal drug delivery actuator should allow for
continuous and reproducible dose adjustment without the
need for cumbersome and bulky external triggers. It should
be robust and functional in a wide range of physiological
conditions for timeframes that extends over months, years or
possibly decades. Moving components, which could be prone
to failure and limit the lifespan of the system, should be
limited. Further, they must require minimal energy
consumption for extended function, minimizing the volume
of batteries and implants. Beyond advanced functionality,
this is important in the context of patient acceptability of the
technology.
To address these needs, here we present a nanofluidic
membrane actuator that leverages electrostatic gating to
control drug release via modulation of membrane
permeability.21 Using fabrication techniques derived from the
semiconductor industry, we developed a silicon carbide (SiC)-
coated membrane featuring a buried doped polysilicon
electrode. The electrode extends under the whole surface of
densely packed nanochannels. The SiC dielectric layer acts as
an electrode insulator providing low leakage currents, thus
reducing energy loss. Further, it provides biocompatibility
and chemical inertness for extended use in an implantable
system. In this study, we characterized the membrane
bioinertness in simulated physiological conditions at 37 °C
and under accelerated setting at 77 °C. To evaluate energy
consumption, we characterized the SiC insulation in
comparison to commonly used SiO2. Finally, we
demonstrated in vitro release rate modulation of three
charged model molecules including Alexa Fluor® 647,
polyĲsodium 4-styrenesulfonate), and DNA. These were chosen
as representative models for small molecule pharmaceutics,
polymeric drug vectors, and surrogate for gene therapy,
respectively. Overall, we present the proof-of-concept of a
robust, ultra-low-power actuator technology capable of
efficient and reproducible control of the release of molecules.
We envision that when integrated with the state-of-the-art
sensing technologies, our gated membrane could provide a
valuable solution to achieve personalized treatment of
patients affected by chronic diseases.
Materials and methods
Nanofluidic membrane fabrication
The membranes employed in this study were fabricated
starting from a 4-inch p-doped silicon-on-insulator (SOI)
substrate with a device layer (10 μm), a buried oxide layer (1
μm) and a handle wafer (400 μm; Ultrasil Corporation,
Hayward, CA). The fabrication steps are illustrated in Fig. 1.
First, a 600 nm thermal oxide was deposited on the surface
of the SOI wafer to act as mask layer for photolithography
(Fig. 1A). Arrays of template nanoslits (500 nm width by 6 um
length) were patterned on the device layer by using standard
photolithography on a contact aligner (SUSS MA6). After
transferring the pattern into the oxide mask layer by reactive
ion etching (RIE), nanoslit patterns were etched through the
10 μm device layer via deep RIE (DRIE) on an ICP deep
silicon etcher (PlasmaTherm, VERSALINE®), and stopped at
the middle oxide of the SOI (Fig. 1B). On the other side of
the SOI, the handle wafer was patterned using double side
alignment on the aligner (SUSS MA6). The layout of the
handle wafer was designed with a high density of hexagonally
arranged circular microchannels to provide mechanical
stability.
ICP deep silicon etching was used to etch through the 400
μm handle wafer, stopping at the buried oxide layer (Fig. 1C).
After cleaning the polymer build up on the sidewalls of
nanoslits and macrochannels, the buried oxide layer of the
SOI was removed in a buffered oxide etchant (BOE) solution
to connect the nanoslits and macrochannel mesh (Fig. 1D).
More details can be found in ESI† note 2. The resulting
nanoslits have a height of 770 nm. Following, a wet thermal
oxidation was performed at 1055 °C in ultra-high-purity
(UHP) water vapor for 11 min, resulting in a high
temperature oxide (HTO) SiO2 formation that shrinks the
nanochannel height to 580 nm (Fig. 1E). To form the gate
electrodes, phosphorus doped polysilicon (poly-Si) was
deposited (121 nm thickness) via low-pressure chemical
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vapor deposition (LPCVD; Fig. 1F). The whole wafer structure
was coated with a 64 nm SiC dielectric layer via plasma-
enhanced chemical vapor deposition PECVD (Fig. 1G). To
expose the highly doped poly-Si, two contacts pads (∼1 mm2)
were created at the edge of the membranes by selective
removal of SiC by fluorine-based RIE.
Each wafer features 120 membrane chips, which were
diced into individual membranes (6 × 6 mm2) via a dicing
Saw (ADT 7100 Dicing Saw). Each chip presents 199 round
microchannels organized in a hexagonal spatial
configuration (Fig. 1H). Every microchannel is connected
to 1400 identical slit nanochannels (length 10 μm)
organized in 19 rows and 96 columns. Each membrane
chip features a total of 278 600 nanochannels.
Membrane degradation
To test the inertness of the membrane in view of
implantable applications, we performed an in vitro study
in simulated physiological conditions at 37 °C as well as
in accelerated conditions at 77 °C. We employed two sets
of membranes: 1) in the first set, the fabrication
procedure was stopped at the thermal oxidation (set A),
resulting in the outmost layer of SiO2 (∼300 nm), 2) the
second set of membranes (set B) featured an outmost
layer of SiC (∼70 nm), which was deposited as previously
described right after SiO2 (∼270 nm) thermal growth.
Each set of membranes was divided into 3 groups: the
first group was soaked in 4 mL of 2 μM sodium fluoride
(NaF) in PBS at 77 °C, the second group was soaked in
the same solution at 37 °C and the third group – in 2
μM NaF in PBS also containing 16 mg mL−1 BSA at 37
°C. This resulted in a total of 6 groups with n = 4
replicates for each. To prevent exposure of SiO2 from the
side in the set B, we covered the sides of each membrane
with thermal epoxy (354-T Epoxy Technologies, Inc.) and
cured at 150 °C for 30 minutes.
The degradation study was run for a total of 120 days with
timepoints every 15 to 30 days depending on the group. At
each timepoint, the membranes were removed from the
solution and triple rinsed in deionized water (DI H2O)
followed by isopropyl alcohol (IPA) before being dried. To
assess degradation, we measured surface roughness (AFM
Catalyst), surface composition (EDAX, Nova NanoSEM 230)
and thickness of the different layers (J. A. Woollam M2000U
ellipsometer).
Focused ion beam (FIB), scanning electron microscope (SEM)
imaging
The structure and fabrication repeatability of the nanofluidic
membrane was assessed by imaging with a dual-ion beam
(FIB) system FEI 235 at the nanofabrication facility of the
University of Houston, Texas. Nanochannel cross sections
were obtained using gallium ion milling. The resulting
structures where imaged at a 52° angle using scanning
electron microscopy (SEM).
Electrode connection
Insulated high-temperature 36 AWG wires (9510T1,
McMaster Carr, Douglasville, GA) were connected to the
exposed contact using conductive silver epoxy (H20E, Epoxy
Technology, MA) and cured at 150 °C for 1 hour. The
conductive contact was then isolated with UV epoxy (OG116,
Epoxy Technologies, Inc.) and cured with a UV lamp (UVL-
18, UVL) for 2 hours.
Fig. 1 Fabrication process schematics. A) Silicon on insulator (SOI)
wafer with lithography mask B) deep reactive ion etching (DRIE) for
nanochannel (nCH) patterning. C) DRIE for microchannel (μCH)
pattern. D) SiO2 mask removal. E) SiO2 thermal oxidation growth. F)
Conductive poly-Si deposition. G) Insulating SiC deposition. H)
Membrane structure.
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Dielectric leakage current
Gate leakage studies were performed in a custom made
two reservoir fixture made of transparent polyĲmethyl
methacrylate) (PMMA) (McMaster Carr, Douglasville, GA).
Each reservoir contains 2 mL of solution. The membrane
under testing was sandwiched between the two reservoirs
by means of two silicon rubber O-rings (Apple Rubber,
Lancaster, NY). The entire assembly was secured together
by 4 SS316L M3 screws. Each reservoir contained two Ag/
AgCl electrodes. Both reservoirs were filled with either
1xPBS, 0.1xPBS or 0.01xPBS solution. The voltage was
applied between the gate electrode (working electrode) and
the two Ag/AgCl electrodes (counter and reference
electrodes) in the reservoir facing the nanochannels using
an electrochemical workstation (CH Instruments, Inc.
660E). A staircase of 250 mV steps was applied from −3 V
and +3 V. Each step was held for 30 s to allow for stable
measurement and avoid confounding effects of transient
phenomena.
Conductance and I–V curves
Conductance and I–V curves were performed in the same
two-reservoir fixture previously described for the leakage
current. Conductance measurements were performed with a
4-electrode configuration, two for each side of the
membrane. We employed KCl solution with concentrations
ranging from 0.1 μM to 100 mM. The solution in both
reservoirs was replaced after each measurement. The
voltages were applied using an electrochemical workstation
(CH Instruments, Inc. 660E). A staircase of 250 mV steps
was applied from −1.5 V and +1.5 V. Each step was held for
30 s to achieve stable measurements unaffected by
transients. The conductance measured as the ratio between
current and applied voltage was calculated for each step
and averaged. Each membrane was tested 3 times. Three
different membranes were tested using the same procedure.
No gate voltage was applied during conductance
measurements.
For current–voltage (I–V) curves we employed a two-
reservoir fixture that featured 3 Ag/AgCl electrodes in one
chamber to serve as a reference for the gate voltage. A 10 μM
KCl solution was employed for these measurements. Voltages
across the membrane (VDS) were applied using an
electrochemical workstation (CH Instruments, Inc. 660E) in
4-electrode configuration. A staircase of 250 mV steps was
applied from −1 V and +1 V. Each step was hold for 30 s to
overcome transient phenomena. The gate voltage was applied
between the gate electrode and the Ag/AgCl electrode in
solution using an electrochemical analyzer (CH Instruments,
Inc. 621D). A constant voltage of either −1.5 V, 0 V or 1.5 V
was applied, and the current monitored.
Both measurements were performed on membranes with
a poly-Si buried electrode and a SiC insulating layer with a
nanochannels size of ∼300 nm.
In vitro release fixture
Release modulation experiments were performed with a
custom made, two reservoirs fixture comprising of a macro
cuvette (sink reservoir) and a drug reservoir. The cuvette was
glued with UV epoxy (OG116, Epoxy Technologies, Inc.) to a
PMMA (McMaster Carr, Douglasville, GA) membrane holder.
The drug reservoir (500 μL capacity), made of PMMA, was
secured to the membrane holder through 2 SS316L M3
screws. The membrane under testing was clamped between
the two PMMA pieces, with 2 O-rings (2418T113, McMaster
Carr, Douglasville, GA) to avoid solution leakage. The
reservoir was capped with a silicone plugs (9277K87,
McMaster Carr, Douglasville, GA).
In vitro release modulation
Release modulation experiments were performed using 300
nm membranes with both poly-Si and SiC deposition. After
the electrode connection, membranes were immersed in
isopropyl alcohol for 1 h to ensure proper channel wetting,
rinsed in deionized H2O at least three times and immersed
in a sink solution of 0.01xPBS overnight. After filling the sink
reservoir with 4.45 mL of 0.01xPBS solution, the membranes
were assembled in the diffusion fixture. The source reservoir
of the diffusion fixture was loaded with either 300 μg mL−1
Alexa Fluor 647 (Thermo Fisher Scientific, Waltham, MA)
(N = 1) in 0.01xPBS, 200 μg mL−1 of polyĲsodium
4-styrenesulfonate) (243051-5G, Sigma Aldrich, St. Louis, MO)
in 0.01xPBS (N = 4) or 1 mg mL−1 of DNA (deoxyribonucleic
acid sodium salt from herring testes; D6898-1G, Sigma
Aldrich, St. Louis, MO) in 0.01xPBS (N = 2). At pH 7.4, all
molecules are negatively charged: −3q (= −4.8 × 10−19 C) for
Alexa Fluor, ∼−380q (= −608 × 10−19 C) for polyĲsodium
4-styrenesulfonate) and highly charged DNA fragment which
charge depends on the fragment length. A proof of concept
release was performed with polyĲsodium 4-styrenesulfonate)
(N = 1) in 1xPBS both in the source and sink reservoir. A
reference Ag/AgCl pellet electrode (Harvard Apparatus,
Holliston, MA) was positioned in the source reservoir.
The assembled diffusion fixtures were then loaded in a
custom robotic carousel22 connected to a Cary 50 UV-vis
spectrophotometer (Agilent Technologies). Absorbance
measurements of the sink reservoir were automatically
performed every 5 minutes. Between each measurement, the
sink solution was under constant stirring to ensure sample
homogeneity. Wavelengths used for detection were 647 nm for
Alexa Fluor, 256 nm for polyĲsodium 4-styrenesulfonate) and
260 nm for DNA. Electrical DC potentials were applied between
the reference and the gate electrode using an arbitrary waveform
generator (Keysight Technologies 33522A) in a succession of
passive (0 V) and active (−1.5 V or −3 V) phases. Phase durations
were 12 h and 8 h for passive and active, respectively. Phases
where shortened for DNA release, due to its high molar
extinction coefficient to 6 h and 4 h for passive and active,
respectively. These shortened phases were also used for the
controlled release of polySS in 1xPBS for a total of 4 cycles.
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Statistical analysis
Graphs were plotted and statistical data analyses were
performed with GraphPad Prism 8 (version 8.1.1; GraphPad
Software, Inc., La Jolla, CA). Data are represented as mean ±
SD. Statistical significance was determined using two-tailed
paired t-tests. For statistical analyses, the cumulative release
of each phase was fitted with a first order polynomial using
MATLAB® polyfit function. The resulting angular coefficient
represent the release rate of the considered phase.
Results and discussion
Nanofluidic membrane
To assess the quality of the fabrication process, all chip
membranes were first visually inspected trough optical
microscopy. We then performed gas test characterization on
all chips to assess the nanochannel dimension uniformity
across the wafer. We employed a previously developed model
to predict the nanochannels dimension from the
measurement of transmembrane nitrogen gas flow upon
application of a pressure difference.23 A Gaussian non-linear
fit (R2 = 0.99) of the cumulative distribution of the obtained
values shows a predicted nanochannel size of 292 ± 44 nm.
Selected chips were further analyzed using FIB-SEM imaging
(Fig. 2). Fig. 2A shows a picture of a single diced chip which
has a size 6 × 6 mm2 and a thickness of 400 μm. The
membrane features 199 cylindrical microchannels which
measure 200 μm in diameter and 390 μm in length.
The hexagonal configuration of the cylindrical
microchannel ensures high channel density and structural
mechanical robustness. Nanochannels are efficiently aligned
in a circular pattern that matched the microchannel area
(Fig. 2B and C). Fig. 2D shows FIB cross sections of the slit
nanochannels where despite the high aspect ratio, all
deposited layers show high uniformity (inset of Fig. 2D). The
innermost SiO2 layer created via slow thermal oxidation
allows for tight control of the nanochannels dimension. The
poly-Si is used as a distributed gate electrode that extends for
the whole nanochannels area to offer high electrostatic
gating performances. External connection to the poly-Si layer
is possible through the conductive pads at the edge of the
chip (Fig. 2A). The outer-most layer of SiC forms an excellent
bio-inert coating, while serving as an insulating layer for the
gate electrodes. As the SiC deposition is performed on both
sides of the wafer, a slightly thicker layer of SiC can be noted
at the entrance and exit of nanochannels due to the limited
diffusivity of precursor gases in nanoconfinement during
deposition. We do not expect this slight non-uniformity to
Fig. 2 Nanofluidic membrane. A) Picture of the nanofluidic membrane which measure 6 mm × 6 mm with a total thickness of 400 μm. B) SEM image
of the top face of the membrane (device layer) that shows the vertically etched nanochannels arranged in circles. C) SEM image of nanochannels array.
D) FIB-SEM image of nanochannel cross-section which shows the vertical nanochannels and highlight the layer stack on the nanochannels walls. In
order from the innermost (silicon, blue) to the outermost layer there is silicon dioxide (SiO2, 175 nm, green), n-doped polycrystalline silicon (poly-Si, 121
nm, red) and silicon carbide (SiC, 64 nm, gray). The different layers in the FIB image are artificially colored for clarity.
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decrease the performance of our membrane, instead, it can
potentially increase it. In fact, as the nanochannel narrows,
the electrostatic effect on charged particles increases,
resulting in a more pronounced gating effect.
As compared to our previous technology24–26 the present
membrane presents two key advantages: i) the streamlined
fluidic structure, with cylindrical microchannels directly
connected to the array of through nanochannels allows for a
substantially simplified fabrication process;27 ii) by
accounting for same nanochannel size, the fluidic
architecture achieves a 45% and 37% reduction in diffusive
length and resistance, respectively. As compared to other
AAO-based gating systems,28 which dispersed pores size can
affect performances,29 the present membrane possesses
monodispersed channel dimensions. This is important in the
context of the tight control of drug delivery. Further, in
contrast to most gated fluidic systems, designed for the
evaluation of electrostatic phenomena,30 our technology
achieves molecular transport rates suitable for medical
applications.
Degradation study
In vitro degradation testing was performed to evaluate the
membrane chemical robustness in view of its application for
implantable drug delivery. The testing conditions in PBS at
37 °C were chosen as they represent an established model of
biological fluids in subcutaneous tissues. Accelerated
conditions at 77 °C allowed us to monitor long-term
degradation within a shorter timeframe, while maintaining
relevance with respect to the physiologic conditions.
Moreover, because fluoride ions are known to readily erode
Fig. 3 Nanofluidic membrane degradation. Energy-dispersive X-ray spectroscopy (EDX) for membranes coated with SiO2 versus SiC at 77 °C (A),
37 °C (D) and at 37 °C with BSA (G). Surface roughness calculated with atomic force microscopy (AFM) for membranes coated with SiO2 versus SiC
at 77 °C (B), 37 °C (E) and at 37 °C with BSA (H). Layer thicknesses fitted through ellipsometry data for membranes coated with SiO2 versus SiC at
77 °C (C), 37 °C (F) and at 37 °C with BSA (I).
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various types of silicon containing materials, we tested
membrane stability in solutions containing NaF. Fluoride is
present in small quantities in drinking water as well as in
physiological fluids. Importantly, in humans, fluoride ions
are not regulated homeostatically and fluoride concentration
in plasma averages at 0.01 ppm.31 We therefore decided to
conservatively use a solution containing almost 4 times the
average fluoride concentration found in human plasma (2
μM).
Fig. 3A, D and G show the surface composition of the
chips analyzed through energy dispersive X-ray spectroscopy
(EDX). For SiO2 chips in accelerated conditions (Fig. 3A), the
relative abundance of silicon and oxygen peaks significantly
changed during the first 30 days, resulting in an increasing
trend of silicon presence. EDX analyses a volume deeper than
the thickness of our SiO2 layer, including the underlying
silicon. Therefore, the shift in composition toward silicon
suggests an erosion of the initial SiO2 layer (∼300 nm). The
reduction in silicon oxide thickness was corroborated by
ellipsometry measurements (Fig. 3C), which show a constant
decreasing trend. However, surface roughness (Fig. 3B) did
not show any significant changes during the first 30 days,
hinting small to no change in solid–liquid interface
composition. Interpolation of the ellipsometry measurements
during the first 30 days yields a corrosion rate of 8.5 nm per
day, which predicts the complete degradation of the silicon
oxide layer in ∼35 days. In fact, the surface roughness
(Fig. 3B) increase after day 30 suggesting a change in surface
composition, likely due to a change in exposed surface from
silicon oxide to silicon. The presence of oxygen in the EDX
for the 45 and 60 days timepoints does not exclude the
hypothesis that the thermal grown oxide is completely
corroded. This can be explained by the formation of Si–O–Si
bonds that occurs due to nucleophilic attack of oxygen from
OH-terminated Si to nearby surface Si atoms with dangling
bonds.32 The silicon surface is concurrently oxidized and
hydrolyzed by the surrounding water. The rate of this
corrosion process is likely higher than the silicon oxide
corrosion rate, resulting in an increased surface roughness as
reported by the AFM measurements (Fig. 3B).
In contrast with SiO2 coating, membranes presenting a
SiC outmost layer did not show appreciable trends of
degradation (Fig. 3A–C). The thickness of SiC measured with
ellipsometry (Fig. 3C) was constant over the whole duration
of the experiment, demonstrating inertness of SiC in
electrolytic solutions, even in the presence of fluoride ions. It
should be noted that EDX revealed a sharp increase in
abundance of carbon concurrent with the reduction of silicon
at 30 days (Fig. 3A). Due to the abrupt rather than continuous
change and the absence of carbon source, we attribute this
observation to a poor fitting of the EDX spectrum which
suffers from suboptimal signal-to-noise ratio.
No notable trends were observed in either the surface
composition or roughness at 37 °C (Fig. 3D and E). However,
the thickness of the silica layer was slowly decreasing as
evident by ellipsometry (Fig. 3F). The degradation rate was
obtained by fitting the data points and is equal to 0.17 nm
per day. To evaluate the effect of the addition of fluorine ions
on degradation we calculated the temperature coefficient (γ)
of silica degradation by assuming linear degradation kinetics
and adopting the Arrhenius equation33 (see ESI† note 2). A
higher value that reported in the literature (typically γ = 2–
2.3)34 was obtained (γ = 2.7), which is indicative of the
harsher degradation conditions generated by fluorine ions.
Even in this setting, SiC coated membrane showed no sign of
degradation, demonstrating superior chemical inertness and
suitability for long-term implantable applications.
Further, we investigated the influence of protein
adsorption on surface degradation (Fig. 3G, H and I).
Membranes were incubated at 37 °C in PBS solution
containing 1.6% BSA, concentration compatible to what
previously reported in the subcutaneous space.35 Ellipsometry
measurements showed no evidence of surface silica loss
throughout the whole duration of the experiment. While in
solution, BSA adsorb to the silica surface, creating a uniform
layer that has been reported to exhibit properties typical of
BSA.36 In these conditions the adsorbate masks the silica
properties and limits the diffusive access of water to the
surface. Thus, protecting the underlying silica from
corrosion.32
Overall, we found that silicon oxide erodes at appreciable
rate in the absence of proteins at 37 °C and very fast at 77
°C. Despite the spontaneous formation of protective protein
layer, it is not reliable for long term use in vivo. In contrast,
silicon carbide showed superior stability and no evidence of
degradation was observed across all tested conditions,
including incubation in 2 μM fluoride buffer at 77 °C.
Gate leakage current, SiO2 vs. SiC
To test the performance of SiC as a dielectric insulator, we
measured gate leakage current and compared it to an
equivalent chip with a SiO2 insulator layer instead of SiC.
SiO2 and in general metal oxides represent the standard for
gate dielectrics in solid electronics.37 However, lack of
durability and reliability of SiO2 in aqueous environment
leads to the adoption of alternative materials such as SiC. As
the leakage current is affected by the ionic strength of the
solution,38 we analyzed leakage for both SiO2 (Fig. 4A) and
SiC (Fig. 4B) at three different ionic strengths.
Fig. 4 Gate leakage current. Gate leakage current at different solution
concentrations for SiO2 dielectric layer (A) and SiC dielectric layer (B).
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Our results clearly show a linear dependence of the
leakage current on the ionic strength of solution for both
dielectric materials, hinting that the origin of this
phenomena lies on the ionic charges in solution. As opposed
to solid electronics where SiO2 and SiC have high intrinsic
breakdown voltages, ∼15 MV cm−1 (ref. 39) and ∼2 MV cm−1
(ref. 40) respectively, we measured leakage currents in the
order of μA for 0.5 MV cm−1. These findings are related to the
‘non-ideality’ of the insulating materials as the presence of
defects and irregularities both in the oxide layer or at the Si–
SiO2 interface can increase the current flow at low electric
fields.41
Although this phenomena has been investigated for more
than 50 years, several aspects of the time-dependent dielectric
breakdown are not yet fully understood, especially in the
presence of aqueous solutions.39 The most accepted theory
(percolation model) postulates that with the application of an
external electric field, electrons are injected and trapped into
the oxide. There they can create clusters that, when within
tunneling distance, create percolating paths (known also as
conductive filaments).42 These lead to increased currents
trough the insulating films.43 In aqueous solutions, formation
of defects can be accelerated by the migration of protons in the
insulating material44 where the dissolution of a percolating
path can create nanometric pores.45 Therefore, high ionic
strength of solution results in a high probability of the defect
formation and thus high leakage currents.
Interestingly, the current for negative applied voltages is
significantly higher than the respective positive voltages
especially for SiC. We attributed this asymmetry to two factors:
1) as a “not ideal” conductor, doped poly-Si suffers from
polydepletion,46 where, a depletion region can form at the poly-
Si/dielectric interface. Depending on the gate voltage,
polydepletion can either help or prevent the channel formation
(in an equivalent MOSFET)47 resulting in the asymmetry we
observed; 2) the mechanism of formation of conductive
filaments inside the insulating material depends on the voltage
applied. With a negative voltage, the electric field pulls protons
from the solution to the solid interface. Protons travel through
the insulator and can interact with electrons when they reach
the insulator/poly-Si interface. This mechanism promotes the
formation of a conductive filament in the insulating material,
resulting in high currents. Conversely, a positive voltage,
pushes the protons toward the solution, resulting in the
breaking of eventual conductive filaments already present
significantly lowering leakage currents.
Both dielectrics seem to be affected by these phenomena.
However, in aqueous environment SiC has the advantage of
being more stable. In light of this, we selected it for the
following experiments.
Mechanism of electrostatically gated diffusion in
nanochannels
Molecular diffusion in nanoconfinement exhibits peculiar
phenomena which are typical of the nanoscale.48,49 Charged
particles electrostatically interact with the charged surfaces of
the nanochannel walls creating an ionic distribution known
as electric double layer (EDL). The EDL can extend several
nanometers into the solution depending on parameters such
as ionic strength and surface charge. In our case, SiO2
exposes negative silanol (SiO−) groups when in aqueous
solution (pH 7.4) resulting in a net negative charge at the
solid/liquid interface.50 Albeit in smaller density, SiC also
exposes negative silanol groups resulting in an interface
behavior similar to SiO2.
51,52 The extent of electrostatic
interaction with the wall has a characteristic dimension
called Debye length and the potential distribution at the
solid–liquid interface is often described using the Poisson–
Boltzmann equation.53 In this region, every charged molecule
electrostatically interacts with the surface charge and their
distribution is such that the nanochannel maintains
electrostatic neutrality. The surface charge dictates the total
concentration of charged molecules in the channel. Thus,
control over the surface charge affords modulation of
nanochannel selectivity toward charged molecules. In
principle, the surface charge could be increased to
completely impede a co-ion from entering the channel,
creating an electrostatic gate.54
The surface charge can be modified by applying a
potential between poly-Si and the electrolyte solution. When
no voltage is applied, free diffusion of negative molecules
occurs (Fig. 5A). When negative potential is applied, the
increase in exposed surface charge results in larger Debye
length and increased repulsion of negatively charged
molecules from the channel (Fig. 5B). The surface charge can
be assessed through membrane conductivity measurements,
while the change in permeability can be investigated
measuring the I–V characteristic.
Electrochemical characterization of the nanofluidic
membrane
To test the ability to modulate the membrane surface charge
we first investigated the ionic conductivity at different
electrolyte concentration and then measured the I–V
characteristics. We employed a custom-made fixture (Fig. 5C)
to hold the membrane between two reservoirs, which and
allows membrane wetting exclusively at the nanochannel
area.
Fig. 5D shows the measured ionic conductance. Two
regimes can clearly be highlighted, the bulk conductance
region and the surface dominated conductance region.55 For
high concentrations, the nanochannel height over Debye
length ratio is h/λ ≫ 1. The measured conductance is
consistent with that of bulk electrolyte solution, and
proportional to its ionic strength. For h/λ ∼ 1 or h/λ < 1,
where the Debye length is comparable with characteristic
dimension of the channel, the conductivity becomes
independent of the ionic strength and channel height. In this
scenario, channels are enriched in counter-ions to
compensate for the surface charge and reach local neutrality.
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Thus, the measured conductance only depends on the
exposed surface charge. For our membranes the transition
between bulk and surface dominated conductance happens
in a 10 μM KCl solution, where the Debye length is expected
to be ∼200 nm. The experimental results are in good
agreement with the known conductance equation:55
I
V
¼ Fμ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Σ
2
 2
þ c02
s
wh
l
where F is Faraday's constant, μ is the ionic mobility, Σ is the
volume charge density, c0 is the molarity of the solution, and
w, h, and l are respectively the width, height, and length of
the nanochannel. Σ was determined by fitting the
experimental data, resulting in a surface charge σs = 0.2 μC
m−2 obtained using the relation zFΣ = −2σs/h and consistent
with what was previously observed.56
Fig. 5E shows representative I–V curves where a clear
dependence of transmembrane current with gate voltage can
be seen. Specifically, we observed an increase in conductance
with the application of a positive gate potential especially for
negative transmembrane voltages. Although unusual for SiO2
nanochannels, where the conductance decreases when a
positive gate voltage is applied, it has been previously
reported and attributed to a slip flow at the wall.57 This
phenomenon happens for SiO2 channels when the external
VDS is intense enough to overcome the attraction of the K
+
ions within the Stern layer and move along the Stern layer,
tangential to the surface. This explanation is further
corroborated by the fact that the SiC surface exhibits a
significantly smaller surface charge (0.2 μC m−2) when
compared to SiO2 (1–100 mC m
−2).58
In vitro release rate modulation of Alexa Fluor 647
As a proof of concept for the controlled release of small
molecule therapeutics, which represent the vast majority of
drugs,59 we investigated Alexa Fluor 647 (AF647). AF647 is a
fluorescent dye that offers high photostability and sensitivity.
AF647 presents a molecular weight of ∼1 kDa, and is a good
surrogate for charged small molecule therapeutics. The
release was performed in a custom-made release fixture
(Fig. 6A) where an external voltage generator (represented as
battery) switched the applied voltage between 0 V and −1.5 V
in alternating phases.
Fig. 5 Electrochemical characterization. A) Concentration driven diffusion of negatively charged molecule. B) Gated diffusion of negatively
charged molecule. C) Rendering of ad hoc device for electrochemical measurements. D) Measured ionic conductance of the membrane. E)
Current–voltage (I–V) curves for the membrane.
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Fig. 6B shows the cumulative release of the negatively
charged AF647 where the passive (12 h) and active (8 h)
phases are highlighted by the blue and red background
respectively. During the passive phases the molecules are
released following a concentration driven diffusion, achieving
a constant release rate. Upon application of the active phase,
co-ions repulsion reduces the concentration of negatively
charged molecules in the channel, AF647 included, resulting
in a reduced transmembrane diffusion. The phase switching
is repeated for 14 cycles, demonstrating repeatability of the
electrostatic gating phenomena. We observed smooth release
rate transitions, which can be attributed to various factors,
including i) capacitive charge/discharge of the poly-Si gate; ii)
transient formation or dissolution of percolating paths in the
dielectric; iii) rearrangement of charged species in
nanochannels. While it is difficult to pinpoint the
contribution of each of these factors, smooth transitions are
desired therapeutic administration. In fact, they can avoid
peak-and-trough plasma fluctuations that can elicit adverse
side effects and negatively impact treatment.60
For ease of comparison, release rates calculated for each
phase form cumulative profiles are plotted in Fig. 6B (bottom
bar graph). To quantify the effect of gating we averaged the
release rate of each phase (horizontal lines) and compared
the active to the passive release. We observed a 60%
reduction of release rate during active phase and an average
release rate of ∼1 μg per day during passive phases. Release
rates in the order of μg per day are in line with daily
therapeutic doses for numerous small molecule therapeutics.
This is the case for glucocorticoids,5 antivirals61 and
hormone therapeutics,62 among others.
In vitro release modulation of polystyrene sulfonate
More than 40% of newly developed drugs are poorly soluble
in water63,64 and require vehicles for their administration. In
this context, to assess the ability of our membrane to
modulate the release of larger molecular constructs such as
drug carriers,65 we adopted polyĲsodium 4-styrenesulfonate).
PolySS (70–1000 kDa) is a polyelectrolyte used for the
treatment of acute and chronic kidney disease66 and for the
encapsulation of pharmacologically active compounds that
exhibit poor water solubility.67,68 Additionally, polySS
presents high exposed charge, which allow for effective
transport modulation via electrostatic gating.
Fig. 7A shows the cumulative release of polySS when
alternating passive (blue) and active phases (brown or red).
During the first 5 active phases (brown) a voltage of −3 V
was applied to the gate electrode, while during the last 3,
the voltage was reduced to −1.5 V. As previously shown for
AF647, the application of a gate voltage consistently
decreased the release rate when compared to the passive
phases, where a sustained release was observed. It is
important to notice how for −3 V the release rate was
almost completely stopped while for −1.5 V the release rate
was considerably reduced, but not interrupted. We
calculated the slope of each cumulative release and then
normalized it to the passive release rate (Fig. 7A, bottom) to
Fig. 6 Modulated release of Alexa Fluor 647. A) Rendering of custom device used for in vitro release rate modulation. B) In vitro cumulative
release modulation of Alexa Fluor (top). Release rate for every phase, normalized to the average of the passive phases. Blue and red line represent
the average of the passive and active (−1.5 V) phases respectively.
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clearly show the differences between the release rates of
active and passive phases. More importantly, the reduction
and restoring of the release upon change of the applied
voltage is consistently repeated demonstrating that
electrostatic gating performances do not degrade over time.
During the passive phases, we measured an average release
rate of 12 μg per day, which is clinically relevant in the
context of hormone replacement therapies.69 In these
applications, our technology could emulate the function of
the body by providing hormone release profiles that mimic
the circadian cycle of hormone secretion.70
In vitro release modulation of DNA salt
To demonstrate the controlled delivery of gene therapeutics
we performed a release study with DNA salt as a surrogate for
plasmid DNA (pDNA) or small interfering RNA (siRNA). pDNA
and siRNA are the two main vectors used in gene therapy for
the treatment of incurable diseases such as cancer or various
genetic disorder.71 Fig. 7B shows the cumulative release of
DNA when alternating passive (blue) and active phases (red).
As for the AF647 and polySS, the application of a negative
voltage (−1.5 V) led to a substantial decrease of release rate
with respect to the passive phase. Release rate analysis and
normalization to the passive phases (Fig. 7B bottom) resulted
in an average reduction of release rate of 50% of the passive
release (Fig. 7B bottom red line). The passive phase yielded
an average release rate of 89 μg per day. A target therapeutic
dose for siRNA cannot be clearly identified, in part due to the
fact that gene silencing therapies are still under
development.72 However, this result provides confidence of
the ability of our system to function in conjunction with
biologics, and control molecular transport at rates that are
within the same order of magnitude of experimental
therapies.73
Performance of release modulation through electrostatic
gating
To better demonstrate the performance of electrostatic
gating, Fig. 8 shows the normalized release rates of the
molecules used in this study, when grouped by applied
Fig. 7 Modulated release of polyĲsodium 4-styrenesulfonate). A) In vitro cumulative release modulation of polySS (top). Release rate for every
phase, normalized to the average of the passive phases (bottom). B) In vitro cumulative release modulation of DNA (top). Release rate for every
phase, normalized to the average of the passive phases. Red line represents the average of the active (−1.5 V) phases.
Fig. 8 Statistical analysis of release modulation. Release rates grouped
by typology and compared.
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voltage. For AF647 the application of −1.5 V resulted in a
∼60% reduction of the release rate.
Similarly, for polySS both applied voltages in the active
phases yielded a significant reduction in release rate of 77%
and a remarkable 98% for −1.5 V and −3 V respectively.
Importantly, for polySS the two active phases lead to a
diffusivity reduction proportional to the intensity of the
applied voltage, which is easily justifiable by different EDL
extents when the surface charge density is changed. In fact, if
the EDL extends to the whole nanochannel volume, co-ions
repulsion results in an almost complete interruption of
analyte diffusion. The analyte charge plays a central role in
gating performances, as a higher charge leads to greater
repulsion forces. Indeed, our results show that polySS yielded
a more pronounced reduction in release rate compared to
AF647 with the application of −1.5 V.
In the case of DNA release, we were also able to show a
statistically significant difference in release rate when
grouping the calculated slopes by phase typology. In this
context, it is remarkable how even despite the presence of
the DNA molecules of different lengths, dimensions and
overall charge, the gating effect produced by our membrane
was consistently and repeatedly able to decrease the diffusion
rate through the nanofluidic channels. Nonetheless, we
recognize that the performance achieved with the modulation
of DNA is slightly less impressive than the one observed with
polySS and we attribute the difference to the lower overall
charge of DNA molecules. In fact, even though we expected a
60–70% reduction with the application of −1.5 V, we achieved
a 50% reduction, likely due to small DNA fragments diffusion
through the bulk region of the nanochannels.
Fig. 8 also shows the release rate modulation of polySS in
PBS solution. We performed this release as a proof of concept
of the ability of our current gated membrane to control drug
release in an environment that mimics in vivo ionic strength
conditions (1xPBS). An average reduction of release rate of
55% was achieved with the application of −1.5 V. Even
though the modulation (decrease) of release rate results less
dramatic as compared to the results obtained with 0.01xPBS
(77% decreased release rate), our results indicate that
electrostatic gating is a viable strategy for drug release
modulation in vivo. Moreover, the same results obtained with
0.01xPBS could be obtained in high ionic strengths fluids
using higher wall potentials or smaller nanochannels. As
increasing the applied potential would increase power
consumption, we intend to adopt smaller nanochannels for
further development of the technology.
It is worth mentioning that although in this study we have
investigated the release modulation of negatively charged
molecules, our membrane can be employed with positive
molecules as well. However, our approach to drug release
modulation is using electrostatic gating to increase the
charge selectivity of channels and effectively generate a
reduction in transport of co-ions. In this context, we start
from negatively charged nanochannels to further increase the
negative surface charge to limit the trans-membrane
diffusion of negative charged species. We chose this
approach as it represents the most energy efficient method to
modulate drug release. While inverting the native silica
surface charge from negative to positive is feasible, this
requires higher applied gating potential and high
corresponding leakage currents.74 In turn, this negatively
affect the energy efficiency of our system. In light of these
consideration, we focused this proof of concept manuscript
on adjusting the release rate of negatively charged molecules
only. The same principle can be applied to positively charged
molecule replacing SiC with a material that exposes positive
charges, such as alumina.
Electrostatic gating energy efficiency
In our analysis, power consumption ranging from 1.5 μW to
45 μW was measured depending on the applied voltage.
Accordingly, commercially available and implant compatible
200 mA h batteries could support implant autonomy from 6
months to a few years, depending on the schedule of applied
voltages. Compared to our previous work,75,76 we were able to
reduce power consumption by almost one order of
magnitude. This was achieved by adopting electrostatic
gating as opposed to electrophoresis or ionic concentration
polarization, which were associated with substantially higher
currents. In electrostatic gating the energy consumption is
determined by leakage currents through the dielectric film.
Materials such as high-k dielectrics can achieve very low
leakage currents. However, they lack biocompatibility and
bioinertness. Thus we chose SiC as it showed exceptional
bioinertness and achieved power consumptions comparable
to previously developed gating devices.29,77
Conclusions and future outlook
Here we presented a nanofluidic membrane that, by
leveraging electrostatic gating, achieves efficient and reliable
release rate modulation of charged analytes. The SiC coating
guarantees superior chemical bioinertness for long-term
implantation78,79 and the high nanochannels density allows
for release rates suitable for medical applications. Moreover,
the proportional response observed between the applied
voltage and release rate reduction offers straightforward
implementation as a drug delivery actuator in sensor-based
systems. In this scenario, membranes can be connected to
control circuitry that autonomously, under remote control, or
with a pre-established schedule can deliver therapeutics
tailored to patient needs.
Our future investigations focus on the integration of the
present technology in our previously developed implantable
device for remote control of drug administration. Upon
successful integration we will move toward in vivo
demonstration of repeatable administration of therapeutic
agents. Moreover, due to unavoidable limited lifespan of
batteries we are exploring alternative strategies for power
source such inductive rechargeable batteries and energy
harvesting from the human body.
Lab on a ChipPaper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
2 
A
pr
il 
20
20
. D
ow
nl
oa
de
d 
on
 4
/1
5/
20
20
 5
:5
5:
53
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Lab ChipThis journal is © The Royal Society of Chemistry 2020
Although further developments are needed, this study
paved the way toward the use of electrostatic gating as a
mean of repeatable modulation of drug delivery. The ability
to reversibly control the permeability of a nanofluidic
membrane with the simple application of an external voltage
renders this technology an ideal actuator for drug delivery. In
fact, it could be integrated with a completely implantable
platform that provides a low-intensity power source that
could either be a rechargeable battery or an energy harvesting
device, avoiding constant external energy supply. This
technology offers promise as a drug delivery actuator for the
next generation of closed-loop drug delivery systems for
personalized medicine.
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